156 related articles for article (PubMed ID: 34233450)
21. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.
Owen CJ; Toze CL; Koochin A; Forrest DL; Smith CA; Stevens JM; Jackson SC; Poon MC; Sinclair GD; Leber B; Johnson PR; Macheta A; Yin JA; Barnett MJ; Lister TA; Fitzgibbon J
Blood; 2008 Dec; 112(12):4639-45. PubMed ID: 18723428
[TBL] [Abstract][Full Text] [Related]
22. RUNX1, but not its familial platelet disorder mutants, synergistically activates PF4 gene expression in combination with ETS family proteins.
Okada Y; Watanabe M; Nakai T; Kamikawa Y; Shimizu M; Fukuhara Y; Yonekura M; Matsuura E; Hoshika Y; Nagai R; Aird WC; Doi T
J Thromb Haemost; 2013 Sep; 11(9):1742-50. PubMed ID: 23848403
[TBL] [Abstract][Full Text] [Related]
23. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.
Manchev VT; Bouzid H; Antony-Debré I; Leite B; Meurice G; Droin N; Prebet T; Costello RT; Vainchenker W; Plo I; Diop M; Macintyre E; Asnafi V; Favier R; Baccini V; Raslova H
J Cell Mol Med; 2017 Jun; 21(6):1237-1242. PubMed ID: 27997762
[TBL] [Abstract][Full Text] [Related]
24. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML).
Owen C
Leuk Res; 2010 Feb; 34(2):141-2. PubMed ID: 19695705
[No Abstract] [Full Text] [Related]
25. Myeloid neoplasms with germ line RUNX1 mutation.
Hayashi Y; Harada Y; Huang G; Harada H
Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
[TBL] [Abstract][Full Text] [Related]
26. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.
Latger-Cannard V; Philippe C; Bouquet A; Baccini V; Alessi MC; Ankri A; Bauters A; Bayart S; Cornillet-Lefebvre P; Daliphard S; Mozziconacci MJ; Renneville A; Ballerini P; Leverger G; Sobol H; Jonveaux P; Preudhomme C; Nurden P; Lecompte T; Favier R
Orphanet J Rare Dis; 2016 Apr; 11():49. PubMed ID: 27112265
[TBL] [Abstract][Full Text] [Related]
27. Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder.
Churpek JE; Garcia JS; Madzo J; Jackson SA; Onel K; Godley LA
Leuk Lymphoma; 2010 Oct; 51(10):1931-5. PubMed ID: 20846103
[No Abstract] [Full Text] [Related]
28. [Familial platelet disorder with predisposition to myeloid leukemia (FPD/AML): a case report and literature review].
Zhang RR; Chen XJ; Ren YY; Yang WY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):308-312. PubMed ID: 33979975
[No Abstract] [Full Text] [Related]
29. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
[TBL] [Abstract][Full Text] [Related]
30. Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.
Krutein MC; Hart MR; Anderson DJ; Jeffery J; Kotini AG; Dai J; Chien S; DelPriore M; Borst S; Maguire JA; French DL; Gadue P; Papapetrou EP; Keel SB; Becker PS; Horwitz MS
Blood Adv; 2021 Feb; 5(3):687-699. PubMed ID: 33560381
[TBL] [Abstract][Full Text] [Related]
31. Familial platelet disorder due to germline exonic deletions in
Engvall M; Karlsson Y; Kuchinskaya E; Jörnegren Å; Mathot L; Pandzic T; Palle J; Ljungström V; Cavelier L; Hellström Lindberg E; Cammenga J; Baliakas P
Leuk Lymphoma; 2022 Oct; 63(10):2311-2320. PubMed ID: 35533071
[TBL] [Abstract][Full Text] [Related]
32. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression.
Bluteau D; Glembotsky AC; Raimbault A; Balayn N; Gilles L; Rameau P; Nurden P; Alessi MC; Debili N; Vainchenker W; Heller PG; Favier R; Raslova H
Blood; 2012 Sep; 120(13):2708-18. PubMed ID: 22898599
[TBL] [Abstract][Full Text] [Related]
33. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract][Full Text] [Related]
35. Integrative analysis of RUNX1 downstream pathways and target genes.
Michaud J; Simpson KM; Escher R; Buchet-Poyau K; Beissbarth T; Carmichael C; Ritchie ME; Schütz F; Cannon P; Liu M; Shen X; Ito Y; Raskind WH; Horwitz MS; Osato M; Turner DR; Speed TP; Kavallaris M; Smyth GK; Scott HS
BMC Genomics; 2008 Jul; 9():363. PubMed ID: 18671852
[TBL] [Abstract][Full Text] [Related]
36. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
[TBL] [Abstract][Full Text] [Related]
37. Validation and clinical application of transactivation assays for RUNX1 variant classification.
Decker M; Agarwal A; Benneche A; Churpek J; Duployez N; Duvall A; Ernst MPT; Förster A; Høberg-Vetti H; Hofmann I; Nash M; Raaijmakers MHGP; Tvedt THA; Vlachos A; Schlegelberger B; Illig T; Ripperger T
Blood Adv; 2022 Jun; 6(11):3195-3200. PubMed ID: 35026845
[TBL] [Abstract][Full Text] [Related]
38. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML).
Shiba N; Hasegawa D; Park MJ; Murata C; Sato-Otsubo A; Ogawa C; Manabe A; Arakawa H; Ogawa S; Hayashi Y
Blood; 2012 Mar; 119(11):2612-4. PubMed ID: 22138511
[TBL] [Abstract][Full Text] [Related]
39. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.
Antony-Debré I; Bluteau D; Itzykson R; Baccini V; Renneville A; Boehlen F; Morabito M; Droin N; Deswarte C; Chang Y; Leverger G; Solary E; Vainchenker W; Favier R; Raslova H
Blood; 2012 Sep; 120(13):2719-22. PubMed ID: 22677128
[TBL] [Abstract][Full Text] [Related]
40. Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.
Jalagadugula G; Mao G; Kaur G; Goldfinger LE; Dhanasekaran DN; Rao AK
Blood; 2010 Dec; 116(26):6037-45. PubMed ID: 20876458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
